Early Prediction of Acute Antidepressant Treatment Response and Remission in Pediatric Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective Less than half of youths achieve remission (minimal to no symptoms) after acute antidepressant treatment. Early identification of who will or will not respond to treatment and achieve remission may help clinicians formulate treatment decisions and shorten the time spent on ineffective treatments. In a prospective open-label fluoxetine study, we investigate indicators of acute treatment response and remission. Method One hundred sixty-eight children and adolescents, ages 7 to 18 years, with primary diagnoses of major depressive disorder received 12 weeks of fluoxetine treatment. The youths were evaluated using the Kiddie Schedule for Affective Disorders and Schizophrenia. The outcome measure included the Children’s Depression Rating Scale-Revised. Results Positive first-degree family history of depression was the only baseline demographic and clinical characteristic that predicted a favorable treatment response (p = .01). The rate of symptom improvement, however, is a good indicator of acute treatment response. A significant symptom reduction (approximately 50%) by week 4 is needed to achieve remission at the end of acute treatment. Conclusions This study demonstrated that the rate of symptom improvement during early weeks of acute fluoxetine treatment is a good indicator of remission. Treatment approach may be reevaluated and modified as early as week 4 during acute treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552
Limbic-cortical dysregulation: a proposed model of depression
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.471 · Cited by 1,585
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707 · cited 1×
“, minimal or no depressive symptoms) is the goal of acute treatment.(1) Previous double-blind placebo-controlled acute pediatric antidepressant trials reveal response rates of 40% to 70%, with remission rates of 30% to 40%.”
BackgroundPLISZKA, S. R., CRISMON, M. L., HUGHES, C. W., CORNERS, C. K., EMSLIE, G. J., JENSEN, P. S., McCRACKEN, J. T., SWANSON, J. M., & LOPEZ, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000215326.51175.eb · Cited by 442
Self-citationFluoxetine versus placebo in preventing relapse of major depression in children and adolescents
Emslie, G. J., Kennard, B. D., Mayes, T. L., Nightingale-Teresi, J., Carmody, T., Hughes, C. W., Rush, A. J., Tao, R., & Rintelmann, J. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091453 · Cited by 188
Self-citationReview of the efficacy and safety of antidepressants in youth depression
Cheung, A. H., Emslie, G. J., & Mayes, T. L. (2005) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2005.01467.x · Cited by 183
Self-citation
Cited by
Comorbidity of anxiety and depression in children and adolescents: 20 years after
Cummings, C. M., Caporino, N. E., & Kendall, P. C. (2014) · Psychological Bulletin · doi:10.1037/a0034733 · Cited by 1,028
“Of interest, comorbid disorders (including anxiety) were not associated with fluoxetine outcomes among youth in three large trials (Cheung et al., 2010; Tao et al., 2009).”
McMakin, D. L., Olino, T. M., Porta, G., Dietz, L. J., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Ryan, N. D., Birmaher, B., et al. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.011 · Cited by 448
Psychometric Properties of the Children's Depression Rating Scale–Revised in Adolescents
Mayes, T. L., Bernstein, I. H., Haley, C. L., Kennard, B. D., & Emslie, G. J. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0063 · Cited by 267
Self-citationTreatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes
Emslie, G. J., Mayes, T., Porta, G., Vitiello, B., Clarke, G., Wagner, K. D., Asarnow, J. R., Spirito, A., Birmaher, B., Ryan, N., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09040552 · Cited by 217
Self-citationHughes, C. W., Barnes, S., Barnes, C., DeFina, L. F., Nakonezny, P., & Emslie, G. J. (2013) · Mental Health and Physical Activity · doi:10.1016/j.mhpa.2013.06.006 · Cited by 132
“Importantly, faster rate of response in the acute phase of treatment is associated with more complete improvement, with those responding to treatment within the first four weeks being more likely to achieve remission after 12 weeks of treatment (Brent et al., 2008; Tao et al., 2009).”
BackgroundSelf-citationMechanisms of antidepressant resistance
El-Hage, W., Leman, S., Camus, V., & Belzung, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00146 · Cited by 111
Metadata
- Authors
- Tao, R., Emslie, G., Mayes, T., Nakonezny, P., Kennard, B., & Hughes, C.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 48
- Issue
- 1
- Pages
- 71-78
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2015486984
- Cited by
- 51
- References
- 11
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.